Background {#Sec1}
==========

Prostate cancer is the second leading male cancer (accounts for 13.8% of all male cancers) and its prevalence ranking number five among all cancers \[[@CR1]\]. In the United States, prostate cancer is the most common male cancer subtype, apart from non-melanoma skin cancer \[[@CR2]\]. Prostate cancer is a clinically heterogeneous disease with marked variability in patient outcomes \[[@CR3]\]. Early detection, accurate prediction and successful management of prostate cancer represent some of the most challenging and controversial issues \[[@CR4]\]. Interestingly, epigenetic changes are hallmarks of prostate cancer, among which DNA methylation is the most frequently studied \[[@CR5]\].

Epigenetic changes include DNA methylation, histone modification, and posttranslational gene regulation by micro-RNAs (miRNAs) \[[@CR6]\]. Among these, DNA methylation has been well studied, and aberrant DNA methylation patterns are a characteristic feature of cancer \[[@CR7]--[@CR9]\]. The first reported epigenetic changes in human cancer were DNA methylation losses. Since then, genomic hypomethylation has been found to be associated with multiple cancer types \[[@CR10], [@CR11]\]. In addition, hypermethylation of CpG islands (CGIs) at promoters of tumor suppressor genes, homeobox genes and other sequences are other consistent epigenetic features of cancer \[[@CR12], [@CR13]\]. CpG island methylator-phenotype (CIMP) tumors have been identified in many cancers, including oral cancer, colorectal cancer \[[@CR14]\] and colon cancer \[[@CR15]\]. Therefore, it is worthwhile to profile the global DNA methylation changes between cancer models and controls to elucidate the mechanisms of carcinogenesis.

The transgenic adenocarcinoma of the mouse prostate (TRAMP) model closely represents the pathogenesis of human prostate cancer because male TRAMP mice spontaneously develop autochthonous prostate tumors following the onset of puberty \[[@CR16]\] and it specifically induces transgene expression in the prostate, displays distant organ metastases and it has castration-resistant properties \[[@CR17]\]. DNA methylation in the TRAMP model has been widely studied in vitro and in vivo, resulting in the discovery of the methylated markers Nuclear factor (erythroid-derived 2)-like 2(NRF2) \[[@CR18]\], O6-alkylguanine DNA alkyltransferase (MGMT) \[[@CR19]\], glutathione S-transferase pi (GSTP1) \[[@CR20]\], 14-3-3σ \[[@CR21]\], and Krueppel-like factor 6 (KLF6) \[[@CR22]\].

However, only Shannon et al. have compared global methylation alteration among TRAMP and wild type (WT) mice \[[@CR23]\]. Systemic comparisons and analyses of the genomic methylation status of prostate cancer models and normal controls are needed to determine the underlying interactions between these target genes and to discover new biomarkers. We are the first to perform methylated DNA immunoprecipitation (MeDIP) coupled with next-generation sequencing (MeDIP-seq) followed by Ingenuity^®^ Pathway Analysis (IPA) studies to investigate the crosstalk among important genes and to analyze overlapping functional pathways by comparing the whole genomic DNA methylation patterns between the TRAMP model and controls.

Methods {#Sec2}
=======

Genomic DNA extraction from TRAMP and C57BL/6 male mice {#Sec3}
-------------------------------------------------------

The breeding of TRAMP mice was same as for our previous studies \[[@CR24], [@CR25]\]. Briefly, female hemizygous C57BL/TGN TRAMP mice, line PB Tag 8247NG (Jackson Laboratory, Bar Harbor, ME), were bred with the same genetic background male C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME). Identity of transgenic mice was established by PCR-based DNA genotyping using the primers suggested by The Jackson Laboratory as we previously described \[[@CR24], [@CR25]\]. F1 (first generation from cross breeding) or F2 (second generation from cross breeding) male TRAMP mice were used for the studies. Mice were housed in cages containing wood-chip bedding in a temperature-controlled room (20--22 °C) with a 12-h-light/dark cycle and a relative humidity of 45--55% at Rutgers Animal Care Facility. All animals received water and food ad libitum until sacrifice (24 weeks of age) by carbon dioxide euthanasia. The study was performed using an IACUC-approved protocol (01-016) at Rutgers University. Mice were weighed and evaluated in the overall health twice weekly throughout the study. Presences of palpable tumor, metastases, genitourinary (GU) apparatus weight were evaluated upon necropsy and prostate intraepithelial neoplasia lesions (evaluated by H&E staining) were monitored in the TRAMP group (data not shown). Prostate samples from three 24-week-old TRAMP and three 24 weeks old C57BL/6 mice (maintained under similar conditions) were randomly selected out. A DNeasy Kit (Qiagen, Valencia, CA, USA) was used to extract the genomic DNA (gDNA) from whole prostate samples of three 24-week-old male TRAMP mice and three age-matched C57BL/6 male mice following the kit's protocol. After extraction and purification, the gDNA samples were electrophoresed on an agarose gel, and the OD ratios were measured to confirm the purity and concentrations of the gDNA prior to fragmentation by Covaris (Covaris, Inc., Woburn, MA USA). The fragmented gDNA was then evaluated for size distribution and concentration using an Agilent Bioanalyzer 2100 and a NanoDrop spectrophotometer.

MeDIP-seq measurement {#Sec4}
---------------------

Following the manufacturer's instructions, MeDIP was performed to analyze genome-wide methylation using the MagMeDIP Kit from Diagenode (Diagenode Inc., Denville, NJ, USA). Methylated DNA was separated from unmethylated fragments by immunoprecipitation with a 5-methylcytidine monoclonal antibody from Eurogentec (Eurogentec S.A., Seraing, Belgium). Illumina libraries were then created from the captured gDNA using NEBNext reagents (New England Biolabs, Ipswich, MA, USA). Enriched libraries were evaluated for size distribution and concentration using an Agilent Bioanalyzer 2100, and the samples were then sequenced on an Illumina HiSeq2000 machine, which generated paired-end reads of 90 or 100 nucleotides (nt). The results were analyzed for data quality and exome coverage using the platform provided by DNAnexus (DNAnexus, Inc., Mountain View, CA, USA). The samples were sent to Otogenetics Corp. (Norcross, GA) for Illumina sequencing and alignment with the reference mouse genome. The resulting BAM files were downloaded for analysis.

Modified from the Trapnell method, the MeDIP alignments were compared with control sample alignments using Cuffdiff 2.0.2 with no length correction \[[@CR26]\]. A list of overlapping regions of sequence alignment that were common to both the immunoprecipitated and control samples was created and used to determine the quantitative enrichment of the MeDIP samples over the control samples using Cuffdiff; statistically significant peaks (reads) at a 5% false discovery rate (FDR) and a minimum fourfold difference, as calculated using the Cummerbund package in R, were selected \[[@CR26]\]. Sequencing reads were matched with the adjacent annotated genes using ChIPpeakAnno \[[@CR27]\], and the uniquely mapped reads were used to compare the differences between TRAMP and wild-type mice.

The reads were visualized and individual genes examined using Integrative Genomics Viewer (IGV) \[[@CR28]\]. IGV allows users to explore aligned reads at any level of details by changing resolution, scrolling through and searching for specific chromosomes, genes or regions \[[@CR29]\]. We specifically examined genes that produced differences in methylation between the TRAMP and control groups of fourfold or more (log2 difference ≥ 2). IGV provided more in-depth understanding of these differences by graphing distributions of reads against the reference genome. Heat maps were used to graphically represent methylation levels in genes and to compare the methylation of the two groups. We used green color to signify positive differences in methylation and the red color for the negative differences (TRAMP minus control). Brighter shades correspond to more extreme values, i.e. larger fold-changes.

Canonical pathways, diseases and function and network analysis by IPA {#Sec5}
---------------------------------------------------------------------

Genes selected from the MeDIP-seq experiment based on significantly increased or decreased fold changes (log2-fold change ≥ 2) in methylation were analyzed (based on the p values; TRAMP vs control) using IPA 4.0 When using IPA (IPA 4.0, ingenuity systems, <http://www.ingenuity.com>), the pathway enrichment *p* value is calculated using the right-tailed Fisher's exact test. A smaller *p* value indicated that the association was less likely to be random and more likely to be significant. In general, values of 0.05 (for *p* value) or 1.30 (for − log~10~p) were set as the thresholds. p values less than 0.05 or − log~10~p more than 1.30 were considered to be statistically significant, non-random associations. IPA utilized gene symbols to identify neighboring enriched methylation peaks using ChIPpeakAnno for all of the analyses. Using IPA, 2147 genes from TRAMP group that showed a log2-fold change ≥ 2 compared with the control group were mapped. Based on these fold changes, IPA identified the canonical pathways, biological functions/related diseases and networks that were closely related to the TRAMP model.

MeDIP-seq data validation via methylation-specific PCR (MSP) {#Sec6}
------------------------------------------------------------

Genomic DNA was extracted and purified from six prostate samples (three from TRAMP mice and three from normal C57BL/6 mice) using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Valencia, CA, USA). Then 500 ng genomic DNA was underwent bisulfite conversion with an EZ DNA Methylation-Gold Kit (Zymo Research Corp., Orange, CA) following the kit's protocol as described previously \[[@CR30]\]. The converted DNA was amplified by PCR using EpiTaq HS DNA polymerase (Clontech Laboratories Inc, Mountain View, CA 94043, USA). According to MeDIP-seq results, four target genes (two with increased methylation and two with decreased methylation), dynein cytoplasmic 1 intermediate chain 1 (DYNC1I1), solute carrier family 1 member 4 (SLC1A4), XRCC6-binding protein 1 (Xrcc6bp1) and transthyretin (TTR), were selected for MSP validation. The primers' sequences for the methylated reactions (MF and MR) and for the unmethylated reactions (UF and UR) and band size of products are listed in Table [1](#Tab1){ref-type="table"}. By running agarose gel electrophoresis, the amplification product bands were isolated and were semi-quantitated by densitometry using ImageJ (Version 1.48d; NIH, Bethesda, Maryland, USA).Table 1Primer sequences used in MSPGene namePrimer namePrimer sequenceBand size (bp)Dync1i1Dync1i1-MFTATGAAGAAAAATATAGTAAGATACGG232Dync1i1-MRACGAACATTTCACATTTCGAADync1i1-UFTTTATGAAGAAAAATATAGTAAGATATGG235Dync1i1-URCACAAACATTTCACATTTCAAASlc1a4Slc1a4-MFATAAATTATTTTTTTTATGTTACGG216Slc1a4-MRTTAATAATACATACCTATAATCCGACSlc1a4-UFATAAATTATTTTTTTTATGTTATGG216Slc1a4-URTTAATAATACATACCTATAATCCAACXrcc6bp1Xrcc6bp1-MFGTTAATGTGAGAGTTAGAATAGTATAGGAC110Xrcc6bp1-MRAATTAATACAATATTTCGATACCGATXrcc6bp1-UFGTTAATGTGAGAGTTAGAATAGTATAGGAT110Xrcc6bp1-URAATTAATACAATATTTCAATACCAATTTRTTR-MFGGAATTTAAGATACGGTTTATATCGA106TTR-MRAACACTCTTTCGAACATACTCGACTTR-UFAGGAATTTAAGATATGGTTTATATTGA108TTR-URAAACACTCTTTCAAACATACTCAACPrimer sequences are started from 5′ (left) to 3′ (right)*MF* forward primer sequence for the methylated reactions, *MR* reverse primer sequence for the methylated reactions, *UF* forward primer sequence for the unmethylated reactions, *UR* reverse primer sequence for the unmethylated reactions

Validation of selected gene expression by quantitative real-time RT-PCR {#Sec7}
-----------------------------------------------------------------------

Total RNA was extracted and purified from six prostate samples (three from TRAMP mice and three from normal C57BL/6 mice) using the same kit above. cDNA was synthesized from total RNA using a SuperScript III First-Strand Synthesis System (Invitrogen, Grand Island, NY) following the kit's instruction. mRNA levels were determined using quantitative real-time PCR (qPCR). Histamine *N*-methyltransferase (HNMT), Dync1i1, SLC1A4, crystallin zeta (CRYZ) and TTR were randomly selected to compare mRNA expression among WT and TRAMP mice prostate samples. The primers' sequences for HNMT, DYNC1I1, SLC1A4, CRYZ, TTR and β-Actin are listed in Table [2](#Tab2){ref-type="table"}.Table 2Primer sequences used in qPCRGene namePrimer namePrimer sequenceHNMTSense5′-GCTGCCAGTGCTAAAATTCTC-3′Antisense5′-CAGGTCATCCAGTATCTGCG-3′DYNC1I1Sense5′-GTGTACGATGTCATGTGGTCC-3′Antisense5′-AACTCGGTTTAG GGCAGATG-3′SLC1A4Sense5′-CCTCACAATTGCCATCATCTT G-3′Antisense5′-CATCCCCTTCCACATTCACC-3′CRYZSense5′-GCAGCCGATGACACTATCTAC-3′Antisense5′-GCCCCATGAACCAAAACG-3′TTRSense5′-AATCGTACTGGAAGACACTTGG-3′Antisense5′-TGGTGCTGTAGGAGTATGG-3′β-ActinSense5′-CGTTCAATACCCCAGCCATG-3′Antisense5′-ACCCCGTCACCAGAGTCC-3′

Results {#Sec8}
=======

MeDIP-seq results comparison {#Sec9}
----------------------------

One of our main goals of this study was to screen and reveal aberrantly methylated genes to discover the related functions and pathways that might mediate the development of prostate cancer. To accomplish this goal in an unbiased manner, the MeDIP-seq results were analyzed using IPA. The first objective was to compare the total number of molecules with altered methylation in prostate samples of TRAMP mice to that of normal mice. Prostate samples were collected from the TRAMP and C57BL/6 mice, gDNA was isolated, and whole-genome DNA methylation analysis was performed using the described MeDIP-seq method. The results were analyzed in a paired manner, comparing the prostate tissue samples for each model. For the control, 16 509 344 (80.8%) mapped and 3 921 684 (19.2%) unmapped reads, for a total of 20 431 028 reads, were obtained. For the TRAMP mice, 12 097 771 (82.3%) mapped and 2 609 269 (17.7%) unmapped reads, for a total of 14 707 040 reads, were obtained (Fig. [1](#Fig1){ref-type="fig"}a). After identification and mapping to the library, the identified methylated regions (peaks) of the given genes were compared between the TRAMP and control mice, and IPA was used to identify the genes with significantly altered methylation in the TRAMP mice compared with the controls (*p* \< 0.05 or − log~10~p \> 1.30, and log2-fold change ≥ 2).Fig. 1Total mapping reads in the control and TRAMP mice (**a**) and the total number of significantly (log2-fold change ≥ 2) increased and decreased methylated genes in the TRAMP mice compared with the control mice (**b**)

Genes were sorted in the order of differences in methylation. Genes with the change in methylation levels of fourfold or more (both, positive and negative) were then used as an input to the IPA software. According to the IPA setting, the *p* value for a given process annotation was calculated by considering (1) the number of focus genes that participated in the process and (2) the total number of genes that are known to be associated with that process in the selected reference set. The more focus genes that are involved, the more likely the association is not due to random chance, resulting in a more significant p value (larger − log~10~p value). Altogether, 2147 genes between the two groups showed a significant change (log2-fold change ≥ 2) in methylated peaks. Compared with the control, significantly decreased methylation of 1105 genes and significantly increased methylation of 1042 genes were observed in TRAMP (Fig. [1](#Fig1){ref-type="fig"}b). The top fifty genes with increased methylation (Table [3](#Tab3){ref-type="table"}) or decreased methylation (Table [4](#Tab4){ref-type="table"}) located in promoter region, gene body or downstream of the gene were highlighted according to the log2-fold change, ranking from the largest to the smallest change and with significant statistic difference (*p* \< 0.05). We also plotted the top 100 decreased or increased (log2-fold change) methylated genes comparing with TRAMP to WT in different regions by MeDIP analysis, ranked by alphabet (Fig. [2](#Fig2){ref-type="fig"}).Table 3Top 50 annotated genes with increased methylation, ranked by log2-fold changeRankSymbolGene nameLog2-fold change (TRAMP/WT)LocationType(s)Methylation region1FGD4FYVE, RhoGEF and PH domain containing 44.993CytoplasmOtherPromoter2MED13LMediator complex subunit 13-like4.993NucleusOtherDownstream3DYNC1I1Dynein, cytoplasmic 1, intermediate chain 14.926CytoplasmOtherBody4XKX-linked Kx blood group4.781Plasma membraneTransporterBody5EAPPE2F-associated phosphoprotein4.703CytoplasmOtherBody6TGFATransforming growth factor, alpha4.534Extracellular spaceGrowth factorPromoter7BTG1B-cell translocation gene 1, anti-proliferative4.440NucleusTranscription regulatorPromoter8BARD1BRCA1 associated RING domain 14.341NucleusTranscription regulatorPromoter9GJA1Gap junction protein, alpha 1, 43 kDa4.341Plasma membraneTransporterPromoter10Zfp640Zinc finger protein 6404.234OtherOtherDownstream11S100A5S100 calcium-binding protein A54.119NucleusOtherPromoter12SOX17SRY (sex-determining region Y)-box 174.119NucleusTranscription regulatorDownstream13PDGFRLPlatelet-derived growth factor receptor-like3.993Plasma membraneKinaseBody14ZKSCAN2Zinc finger with KRAB and SCAN domains 23.993NucleusTranscription regulatorPromoter15DMXL2Dmx-like 23.926CytoplasmOtherBody16LEPRLeptin receptor3.926Plasma membraneTransmembrane receptorBody17AOAHAcyloxyacyl hydrolase (neutrophil)3.855Extracellular spaceEnzymePromoter18Apol7eApolipoprotein L 7e3.855OtherOtherBody19CACNG6Calcium channel, voltage-dependent, gamma subunit 63.855Plasma membraneIon channelPromoter20CHCHD3Coiled-coil-helix-coiled-coil-helix domain containing 33.855CytoplasmOtherBody21FAM174BFamily with sequence similarity 174, member B3.855OtherOtherBody22GALNT13Polypeptide *N*-acetylgalactosaminyltransferase 133.855CytoplasmEnzymeBody23GPR37G protein-coupled receptor 37 (endothelin receptor type B-like)3.855Plasma membraneG-protein coupled receptorDownstream24Mup1Major urinary protein 13.855Extracellular spaceOtherDownstream25NGFNerve growth factor (beta polypeptide)3.855Extracellular spaceGrowth factorDownstream26OLFM3Olfactomedin 33.855CytoplasmOtherBody27PCBP3Poly(rC)-binding protein 33.855NucleusOtherBody28RBMS3RNA-binding motif, single-stranded-interacting protein 33.855OtherOtherBody29TMX1Thioredoxin-related transmembrane protein 13.855CytoplasmEnzymeDownstream30ZNF14Zinc finger protein 143.855NucleusTranscription regulatorBody31SLC1A4Solute carrier family 1 (glutamate/neutral amino acid transporter), member 43.807Plasma membraneTransporterBody32ZFAND3Zinc finger, AN1-type domain 33.717OtherOtherBody33C1orf162Chromosome 1 open reading frame 1623.703OtherTransporterPromoter34C9orf131Chromosome 9 open reading frame 1313.703OtherOtherBody35CRYZCrystallin, zeta (quinone reductase)3.703CytoplasmEnzymeBody36CYP2A6Cytochrome P450, family 2, subfamily A, polypeptide 63.703CytoplasmEnzymeBody37CYP51A1Cytochrome P450, family 51, subfamily A, polypeptide 13.703CytoplasmEnzymeDownstream38DSPPDentin sialophosphoprotein3.703Extracellular spaceOtherPromoter39GALNT3Polypeptide *N*-acetylgalactosaminyltransferase 33.703CytoplasmEnzymeDownstream40Gm4836Predicted gene 48363.703NucleusOtherDownstream41GRIP1Glutamate receptor-interacting protein 13.703Plasma membraneTranscription regulatorPromoter42GUCY1A2Guanylate cyclase 1, soluble, alpha 23.703CytoplasmEnzymeBody43HNMTHistamine *N*-methyltransferase3.703CytoplasmEnzymeBody44LRRC8BLeucine-rich repeat containing 8 family, member B3.703OtherOtherBody45MEF2AMyocyte enhancer factor 2A3.703NucleusTranscription regulatorBody46NRG3Neuregulin 33.703Extracellular spaceGrowth factorPromoter47PCDH17Protocadherin 173.703OtherOtherPromoter48PDP2Pyruvate dehydrogenase phosphatase catalytic subunit 23.703CytoplasmPhosphatasePromoter49SH2D4BSH2 domain containing 4B3.703OtherOtherBody50Smok2bSperm motility kinase 2B3.703OtherKinaseBody Table 4Top 50 annotated genes with decreased methylation, ranked by log2-fold changeRankSymbolGene nameLog2 fold change (TRAMP/WT)LocationType(s)Methylation region1Rrbp1Ribosome-binding protein 1− 5.824CytoplasmTransporterBody2CISD2CDGSH iron sulfur domain 2− 4.373CytoplasmOtherDownstream3NR4A1Nuclear receptor subfamily 4, group A, member 1− 4.324NucleusLigand-dependent nuclear receptorBody4LCMT1Leucine carboxyl methyltransferase 1− 4.051CytoplasmEnzymeBody5XRCC6BP1XRCC6 binding protein 1− 3.990OtherKinaseDownstream6TTRTransthyretin− 3.926Extracellular spaceTransporterPromoter7ZNF536Zinc finger protein 536− 3.859OtherOtherDownstream8FARP1FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived)− 3.788Plasma membraneOtherBody9TNRC18Trinucleotide repeat containing 18− 3.788OtherOtherBody10FOXL1Forkhead box L1− 3.714NucleusTranscription regulatorDownstream11ZMAT4Zinc finger, matrin-type 4− 3.714NucleusOtherPromoter12ABCC2ATP-binding cassette, sub-family C (CFTR/MRP), member 2− 3.636Plasma membraneTransporterBody13AMFRAutocrine motility factor receptor, E3 ubiquitin protein ligase− 3.636Plasma membraneTransmembrane receptorDownstream14ARSKArylsulfatase family, member K− 3.636Extracellular spaceenzymeBody15GRM3Glutamate receptor, metabotropic 3− 3.636Plasma membraneG-protein coupled receptorPromoter16HTR1F5-hydroxytryptamine (serotonin) receptor 1F, G protein-coupled− 3.636Plasma membraneG-protein coupled receptorBody17CC2D2ACoiled-coil and C2 domain containing 2A− 3.554OtherOtherPromoter18CSMD1CUB and Sushi multiple domains 1− 3.554Plasma membraneOtherBody19HIBCH3-Hydroxyisobutyryl-CoA hydrolase− 3.554CytoplasmEnzymeBody20NMT2*N*-Myristoyltransferase 2− 3.554CytoplasmEnzymePromoter21PCDH20Protocadherin 20− 3.554OtherOtherPromoter22PDCD1Programmed cell death 1− 3.554Plasma membranePhosphatasePromoter23QRFPPyroglutamylated RFamide peptide− 3.554Extracellular spaceOtherDownstream24REG3GRegenerating islet-derived 3 gamma− 3.554Extracellular spaceOtherDownstream25TLR4Toll-like receptor 4− 3.554Plasma membraneTransmembrane receptorDownstream26TNRC6BTrinucleotide repeat containing 6B− 3.554OtherOtherBody27CCR3Chemokine (C--C motif) receptor 3− 3.466Plasma membraneG-protein coupled receptorPromoter28Cngb1Cyclic nucleotide gated channel beta 1− 3.466OtherOtherBody29CNTNAP5Contactin associated protein-like 5− 3.466OtherOtherBody30Cox7cCytochrome *c* oxidase subunit VIIc− 3.466CytoplasmOtherPromoter31EIF4EBP1Eukaryotic translation initiation Factor 4E binding protein 1− 3.466CytoplasmTranslation regulatorDownstream32FGF10Fibroblast growth factor 10− 3.466Extracellular spaceGrowth factorDownstream33GNAI1Guanine nucleotide-binding protein (G protein), alpha inhibiting activity polypeptide 1− 3.466Plasma membraneEnzymePromoter34Ins1Insulin I− 3.466Extracellular spaceOtherPromoter35ITGA8Integrin, alpha 8− 3.466Plasma membraneOtherBody36JAG1Jagged 1− 3.466Extracellular spaceGrowth factorPromoter37Pcdh10Protocadherin 10− 3.466OtherOtherPromoter38PPP1R17Protein phosphatase 1, regulatory subunit 17− 3.466CytoplasmOtherDownstream39Serbp1Serpine1 mRNA-binding protein 1− 3.466CytoplasmOtherPromoter40WaslWiskott-Aldrich syndrome-like (human)− 3.466CytoplasmOtherPromoter41ABAT4-Aminobutyrate aminotransferase− 3.373CytoplasmEnzymeBody42ANKMY2Ankyrin repeat and MYND domain containing 2− 3.373Plasma membraneOtherDownstream43Card11Caspase recruitment domain family, member 11− 3.373OtherOtherBody44CDK5R1Cyclin-dependent kinase 5, regulatory subunit 1 (p35)− 3.373NucleusKinaseDownstream45DACH1Dachshund family transcription factor 1− 3.373NucleusTranscription regulatorDownstream46FGGYFGGY carbohydrate kinase domain containing− 3.373OtherOtherBody47GADD45GGrowth arrest and DNA-damage-inducible, gamma− 3.373NucleusOtherDownstream48GLRBGlycine receptor, beta− 3.373Plasma membraneIon channelBody49LRRTM1Leucine-rich repeat transmembrane neuronal 1− 3.373Plasma membraneOtherDownstream50NEDD4LNeural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase− 3.373CytoplasmEnzymeBody Fig. 2Heat-map of top 100 decreased or increased (log2-fold change) methylated genes comparing with TRAMP to WT in different regions by MeDIP analysis, ranked by alphabetic

Four genes of interest, DYNC1I1, SLC1A4, XRCC6BP1 and TTR were analyzed by IGV (Fig. [3](#Fig3){ref-type="fig"}), which provides more in-depth understanding of these differences between TRAMP and control mice. The IGV results are in accordance with the MeDIP-seq finding. In TRAMP mice, the methylation ratio of DYNC1I1 and SLC1A4 were increased, whereas the methylation ratio of TTR and XRCC6BP1 were decreased. The methylation results have been validated by MSP.Fig. 3integrative genomics viewer visualization of the aligned reads' distribution against reference genome for four targeted genes: DYNC1i1, SLC1A4, TTR and XRCC6BP1

These results demonstrate a fundamental difference in the global pattern of gene methylation between the TRAMP prostate tumor and control prostate tissue. The potential impact of this difference was further assessed using IPA by analyzing the canonical pathways, diseases and functions, and networks related to these methylation changes.

MeDIP-seq data validation by MSP {#Sec10}
--------------------------------

According to the MeDIP-seq results, four interesting genes, two with increased methylation (TRAMP vs WT), DYNC1I1 and SLC1A4, and two with decreased methylation (TRAMP vs WT), XRCC6BP1 and TTR were selected to carry out MSP to validate the MeDIP-seq data. MSP results indicated a similar trend in agreement with the MeDIP-seq results.

The results showed, in Dync1i1 and Slc1a4 genes, the relative density of M-MSP (methylated MSP) to that of U-MSP (unmethylated MSP) in TRAMP group were increased, which indicated that the CpG sites of these genes were hypermethylated in TRAMP mice (Fig. [4](#Fig4){ref-type="fig"}). Similarly, in Xrcc6bp1 and TTR, the relative density of M-MSP to that of U-MSP in TRAMP group was decreased, which indicated that the CpG sites of these genes were hypomethylated in TRAMP mice (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Medip-Seq Validation by methylation-specific PCR (MSP). Representative electrophoretogram is presented in the top panel. M-MSP: methylated reaction of MSP, U-MSP: unmethylated reaction of MSP. The relative intensity of the methylated and unmethylated band was measured by ImageJ and presented in the bottom panel. All of the data are presented as the mean ± SD. \**p* \< 0.05 vs the control WT group

qPCR validation of selected gene expression {#Sec11}
-------------------------------------------

When mRNA levels were measured by qPCR, the relative expression levels of CRYZ, DYNC1I1, HNMT, SLC1A4 and TTR in TRAMP group were 0.62, 1.90, 0.15, 0.15 and 9.05 fold compared with WT (Fig. [5](#Fig5){ref-type="fig"}). Among these, TTR expression was increased by 9.05-fold over WT, which agreed with results reported by Wang et al. \[[@CR31]\] that expression levels of TTR were significantly higher in prostate cancer tissue than in normal and benign prostate hyperplasia tissue. When comparing mRNA expression and Methylation validation results, reciprocal relationships were found in TTR in TRAMP, which indicated decreased methylation in promoter region but increased gene expression when comparing with WT. In contrast, DNA methylation in the gene body or downstream may or may not follow a reciprocal relationship with gene expression as described in the findings of Jiang et al. \[[@CR32]\]. It is expected that individual genes may be differentially affected by CpG methylation and that only global analysis would be expected to reveal overall patterns likely to emerge.Fig. 5Comparison of mRNA expression of CRYZ, DYNC1I1, HNMT, SLC1A4 and TTR among WT and TRAMP mice prostate samples. Total mRNA was isolated and analyzed using quantitative real-time PCR. The data are presented as the mean ± SD of three independent experiments. \**p* \< 0.05 vs the control WT group

Canonical pathway, diseases and functions and network analyses by IPA {#Sec12}
---------------------------------------------------------------------

The 2147 genes with remarkable change in methylation (log2-fold change ≥ 2) were analyzed using the IPA software package. When using IPA, canonical pathways, which are based on the literature and are generated prior to data input, are the default settings. These pathways do not change upon data input and have a directionality-linked list of interconnected nodes. By contrast, networks are generated de novo based upon input data, lack directionality and contain molecules that are involved in a variety of canonical pathways.

The genes within the canonical pathways were ranked by the possibility parameter, i.e., the --log~10~(p) value in the corresponding pathway, and are presented in Table [5](#Tab5){ref-type="table"}. The CREB1 gene, which is involved the neuropathic pain signaling pathway, was ranked first. The top networks ranked based on their ratios of methylated gene/total gene are listed in Table [6](#Tab6){ref-type="table"}. Of the networks, HDAC2-related, tissue morphology, embryonic development, and organ development network was ranked first (Table [6](#Tab6){ref-type="table"}). Among the networks, the cancer-related networks accounted for the majority (15/25) (Table [6](#Tab6){ref-type="table"}), which indicates that the great difference between the TRAMP and control lies in organ development and cancer development.Table 5Top ten altered canonical pathways, sorted by − log~10~ (p) value via IPAPathways− Log~10~ (p value)Involved moleculesNeuropathic pain signaling in dorsal horn neurons3.01TACR1, GRM7, KCNN3, CAMK1D, MAPK1, GPR37, BDNF, GRM3, GRIA1, CREB1, TAC1, GRIN3ACardiomyocyte differentiation via BMP receptors3.01NKX2-5, MAP3K7, SMAD6, MEF2C, BMP10cAMP-mediated signaling2.75ENPP6, ADCY2, RGS18, MAPK1, CAMK1D, PTGER3, GRM3, DUSP6, GNAI1, CHRM3, Cngb1, GRM7, FSHR, RGS10, CREB1, HTR1F, DRD3, PTGER4, PPP3CAEstrogen biosynthesis2.64CYP4F8, CYP3A5, HSD17B7, CYP2C9, CYP2A6 (includes others), CYP51A1, CYP2C8PXR/RXR activation2.63CYP3A5, ABCC2, INS, CYP2C9, CYP2A6 (includes others), INSR, PAPSS2, Ins1, CYP2C8Wnt/β-catenin signaling2.43CDKN2A, GJA1, WNT3, APPL2, APC, SOX17, SOX2, FZD8, PPP2R1A, WNT7A, RARB, TLE4, MAP3K7, NR5A2, GSK3BBMP signaling pathway2.43MAP2K4, NKX2-5, MAPK1, BMP8A, CREB1, MAP3K7, SMAD6, GREM1, BMP10Factors promoting cardiogenesis in vertebrates2.41FZD8, SMAD2, NKX2-5, WNT3, BMP8A, MAP3K7, MEF2C, GSK3B, BMP10, APCGlutamate receptor signaling2.40GRM7, SLC1A4, GRM3, GRIA1, SLC38A1, GRIP1, GRIK2, GRIN3AHuman embryonic stem cell pluripotency2.39SOX2, FZD8, SMAD2, WNT7A, WNT3, BDNF, BMP8A, SMAD6, GSK3B, NGF, APC, INHBA, BMP10LPS/IL-1 mediated inhibition of RXR function2.37MAP2K4, GAL3ST2, ABCC2, CYP2C9, APOC2, NDST4, PAPSS2, IL1R2, TLR4, UST, CYP3A5, Sult1c2 (includes others), MAP3K7, NR5A2, CYP2A6 (includes others), GSTP1, MAOA, CYP2C8 Table 6Top networks analyzed by IPARankTop diseases and functionsScore1Tissue morphology, embryonic development, organ development382Cell-to-cell signaling and interaction, cell signaling, cellular function and maintenance383Cell death and survival, cancer, cell morphology374Cancer, gastrointestinal disease, cell death and survival355Cancer, carbohydrate metabolism, small molecule biochemistry336Cancer, cell death and survival, cellular response to therapeutics337Lymphoid tissue structure and development, organ morphology, organismal development308Cancer, gastrointestinal disease, post-translational modification299Cancer, dermatological diseases and conditions, gastrointestinal disease2910Cell morphology, digestive system development and function, nervous system development and function2811Cancer, gastrointestinal disease, cell death and survival2612Cancer, drug metabolism, energy production2613Cell-to-cell signaling and interaction, nervous system development and function, cellular development2614Cellular movement, cellular development, skeletal and muscular system development and function2415Cell death and survival, cancer, cellular development2416Hereditary disorder, inflammatory response, metabolic Disease2217Cell morphology, nervous system development and function, tissue morphology2118Cancer, organismal injury and abnormalities, reproductive system disease2119Cellular compromise, cancer, cardiovascular disease1920Cell-to-cell signaling and interaction, tissue development, hematological system development and function1721Cancer, organismal survival, organismal injury and abnormalities1622Cellular assembly and organization, cellular function and maintenance, embryonic development1623Cancer, organismal injury and abnormalities, reproductive system disease1624Cell cycle, cellular movement, cancer1625Cancer, developmental disorder, hereditary disorder16

Diseases and functions refer to the most likely linked diseases or functions based on statistics. Similar to the network analysis, for the most associated disease based on the ranking of − log~10~p, cancer, gastrointestinal disease, organismal abnormalities, reproductive system disease and dermatological diseases were ranked within the top five (Fig. [6](#Fig6){ref-type="fig"}a). Of all cancer subtypes, adenocarcinoma ranked first (Fig. [6](#Fig6){ref-type="fig"}b), which was consistent with the TRAMP model, which is a model for prostate adenocarcinoma.Fig. 6Top five associated disease categories (**a**) and top five cancer subtypes (**b**) analyzed by IPA

Discussion {#Sec13}
==========

Analysis of canonical pathway would provide further understanding of disease and information for the development of new therapeutic targets {#Sec14}
-------------------------------------------------------------------------------------------------------------------------------------------

As shown in Fig. [7](#Fig7){ref-type="fig"}, the genes with significantly altered methylation in the top canonical pathway was the neuropathic pain signaling pathway, as mapped by IPA. This finding is consistent with Chiaverotti's finding indicating that the most common malignancy in TRAMP is of neuroendocrine origin \[[@CR33]\]. Table [7](#Tab7){ref-type="table"} lists the genes involved in this pathway that exhibited modified methylation. Among these, methylation of the CREB1 gene was found to be decreased by 2.274-fold (log2) by MeDIP-seq in TRAMP.Fig. 7Genes mapped to the canonical neuropathic pain signaling pathway by IPA. Red, increased methylation; green, decreased methylation (for interpretation of the references to color in the figure legend, please refer to the online version of this article) Table 7Altered methylation genes mapped to the neuropathic pain signaling pathway by IPASymbolGene nameLog2-fold changeType(s)GRM3Glutamate receptor, metabotropic 3− 3.636G-protein-coupled receptorGRIA1Glutamate receptor, ionotropic, AMPA 1− 3.167Ion channelBDNFBrain-derived neurotrophic factor− 2.373Growth factorCREB1cAMP-responsive element-binding protein 1− 2.274Transcription regulatorGRM7Glutamate receptor, metabotropic 7− 2.274G-protein-coupled receptorGRIN3AGlutamate receptor, ionotropic, N-methyl-D-aspartate 3A− 2.129Ion channelMAPK1Mitogen-activated protein kinase 12.048KinaseTAC1Tachykinin, precursor 12.408OtherCAMK1DCalcium/calmodulin-dependent protein kinase ID2.855KinaseTACR1Tachykinin receptor 12.855G-protein-coupled receptorKCNN3Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 33.119Ion channelGPR37G protein-coupled receptor 37 (endothelin receptor type B-like)3.855G-protein-coupled receptor

CREB was first found to be closely related to cellular proliferation, differentiation and adaptive responses in the neuronal system \[[@CR34], [@CR35]\]. Subsequently, increasing evidence revealed that CREB is directly involved in the oncogenesis of a variety of cancers by regulating the immortalization and transformation of cancer cells \[[@CR36], [@CR37]\].

CREB is also found to modulate other carcinogenesis pathways. S100 calcium binding protein P (S100P) is a calcium-binding protein that is associated with cancer, and functional analysis of the S100P promoter identified SMAD, signal transducer and activator of transcription (STAT)/CREB and SP/KLF binding sites as key regulatory elements in the transcriptional activation of the S100P gene in cancer cells \[[@CR38]\]. *Homo sapiens* lactate dehydrogenase c (hLdhc) was reported to be expressed in a wide spectrum of tumors, including prostate cancers, and this expression was shown to be regulated by transcription factor Sp1 and CREB as well as promoter CpG island (CGI) methylation \[[@CR39], [@CR40]\]. Decreased prostate tumorigenicity was found to be correlated with decreased expression of CREB and its targets, including Bcl-2 and cyclin A1.

Clinically, upregulation of CREB was found in various human cancer samples including prostate cancer, breast cancer, non-small-cell lung cancer and acute leukemia, whereas down-regulation of this gene manifested inhibition of some cancer cells \[[@CR41]\].

All of these data indicate that CREB is highly associated with cancer therapy. Our study demonstrated that CREB gene methylation is significantly decreased in the TRAMP model, which suggests a new approach to prostate cancer prevention and therapy.

Novel networks involving the methylation of target genes could provide new insights for prostate cancer {#Sec15}
-------------------------------------------------------------------------------------------------------

Compared with the canonical pathways, networks are generated de novo based upon input data and are able to more flexibly reveal the interactions of altered genes and functions. As it is impossible to analyze all networks listed in Table [6](#Tab6){ref-type="table"}, four interesting networks were elaborated below (the higher the score is, the more genes with altered methylation are involved in the network). Among all these networks, many genes are known to be highly associated with tumor onset and progression, however, our insight into their methylation status alteration would reveal novel biomarkers for prostate tumorigenesis.

### HDAC2-related network (score = 38) {#Sec16}

The top network identified by IPA, was the HDAC2-related tissue morphology, embryonic development and organ development network (Table [6](#Tab6){ref-type="table"}, Fig. [8](#Fig8){ref-type="fig"}a). In this network, the HDAC2 gene, a key member of HDAC, exhibited 3.274-fold (log2) decreased methylation in TRAMP. HDACs are responsible for the removal of acetyl groups from histones and play important roles in modulating the epigenetic process by influencing the expression of genes encoded by DNA bound to a histone molecule \[[@CR42]\]. HDAC inhibitors have also been shown to reduce colonic inflammation \[[@CR43]\], inhibit cell proliferation, and stimulate apoptosis, and these inhibitors represent a novel class of therapeutic agents with antitumor activity that are currently in clinical development \[[@CR44], [@CR45]\]. By upregulating histone H3 acetylation and p21 gene expression, long-term treatment with MS-275, an HDAC inhibitor, attenuated the progression of prostate cancer in vitro and in vivo \[[@CR46]\]. Another HDAC inhibitor, OSU-HDAC42, also showed a chemoprevention effect on prostate tumor progression in the TRAMP model \[[@CR47]\]. Our data suggest that the altered methylation of HDAC (3.274 log2-fold decrease) might be a novel, interesting target for prostate cancer treatment. Based on our MeDIP-seq results, HNMT in this network was increased by 3.703-fold (log2). In addition, based on our qPCR analysis, HNMT gene expression was reduced by 6.67-fold, which supports the likelihood of a role of HNMT in prostate cancer. However, although HNMT has been demonstrated to be associated with breast cancer \[[@CR48]\] and liver cancer \[[@CR49]\], little is known about its potential role in prostate cancer, making it another potential novel marker.Fig. 8HDAC2 network (score = 38) (**a**), GSTP1 network (score = 16) (**b**), and UBC network (score = 16) (**c**), as determined by IPA. Red, increased methylation; green, decreased methylation (for interpretation of the references to color in the figure legend, please refer to the online version of this article)

### GSTP1-related network (score = 16) {#Sec17}

GSTP1 expression is inactivated in prostate cancers \[[@CR50]--[@CR52]\], and this inactivation is associated with hypermethylation of GSTP1 CpG islands \[[@CR51], [@CR52]\]. Clinically, higher GSTP1 promoter methylation was found to be independently associated with the risk of prostate cancer \[[@CR53]\]; therefore, the detection of hypermethylated GSTP1 in urine and semen samples can be a diagnostic marker of prostate cancer \[[@CR54]\]. We also found that methylation of GSTP1 was an important factor involved in prostate cancer development. Interestingly, based on our data, the methylation of the GSTP1 gene was decreased 2.274-fold (log2) in TRAMP. Figure [8](#Fig8){ref-type="fig"}b demonstrates the decreased methylation of GSTP1. Based on comparisons of prostate samples from TRAMP and strain-matched WT mice, Mavis et al. \[[@CR20]\] showed that promoter DNA hypermethylation does not appear to drive GST gene repression in TRAMP primary tumors. The above results support our finding that the methylation status of GSTP1 may differ in humans. DYNC1I1, which was also in the network, exhibited a 4.926-fold (log2) increase in methylation. In qPCR analysis, it indicates a 1.9-fold increase in gene expression. Although DYNC1I1 is significantly up-regulated in liver tumors \[[@CR55]\] but not in prostate tumors, our findings suggest that it may be the next useful prostate cancer biomarker.

### UBC-related network (score = 16) {#Sec18}

Another interesting network was found surrounding the UBC gene (Fig. [8](#Fig8){ref-type="fig"}c); however, UBC itself was not identified by MeDIP-seq. The methylation of solute carrier family 1 member 4 (SLC1A4) and CRYZ was highly up-regulated (3.807 and 3.703 log2-fold increased, respectively). According to qPCR results, the expressions of SLC1A4 and CRYZ in TRAMP group were only 0.15- and 0.62-fold of WT group. SLC1A4 was found to be associated with human hepatocellular carcinoma \[[@CR56]\], and CRYZ was proven to be involved in B-cell lymphoma 2 (BCL-2) overexpression in T-cell acute lymphocytic leukemia \[[@CR57]\]. Although an association with prostate cancer was not found, our MeDIP--seq findings in the TRAMP model suggest that this association is possible.

### Merged networks overlaid with IPA settings could even predict the direction of the relationship {#Sec19}

When merging the two interesting networks HDAC2 and GSTP1 and overlaying the molecular activity predictor of IPA (Fig. [9](#Fig9){ref-type="fig"}), tumor protein 53 (TP53) was found to be located in the center of the novel network, indicating the potential important modulating function of TP53 on HDAC2 and GSTP1. TP53 is encoded by p53, a tumor suppressor gene located on chromosome 17p13, which is one of the most frequently mutated genes in multiple cancers \[[@CR58]--[@CR60]\]. TP53 acts as a transcription factor that mediates the response to various cellular stresses, most importantly, the DNA damage response \[[@CR61]\]. TP53 has also been proven to play a crucial role in prostate cancer development and progression \[[@CR62]--[@CR64]\].Fig. 9Merged network of the HDAC2 and GSTP1 networks, as determined by IPA. Red, increased methylation; green, decreased methylation (for interpretation of the references to color in the figure legend, please refer to the online version of this article)

The interactions between GSTP1, HDAC and TP53 have been studied in prostate disease models. In prostatectomy specimens of 30 benign prostatic hyperplasia patients, the increase in TP53 expression at the same site was accompanied by an increase in GSTP1 expression \[[@CR65]\]. In the 3 human prostate cancer cell lines DU-145, PC-3 and LNCaP, As~2~O~3~ was found to increase TP53 expression only in LNCap cells (without GSTP1 expression) but not in DU-145 and PC-3 cells (both cells expressed GSTP1) \[[@CR66]\]. In LNCaP cells, the acetylation of human TP53 increased the binding of promoter fragments of the human P21 gene that contained a p53 response element and of the human HDAC2 protein \[[@CR67]\].

Although the relationships between TP53 and HDAC2 as well as GSTP1 in prostate cancer have been elucidated, these relationships in the TRAMP model remain unknown. Our predicated interactions among these proteins in TRAMP suggest the possibility that TP53 influences the methylation of GSTP1 and HDAC2, which is a potential direction of future research.

Conclusions {#Sec20}
===========

To the best of our knowledge, this is the first MeDIP-seq study to analyze the DNA methylation differences of prostate cancer by comparing TRAMP mice, an adenocarcinoma prostate cancer model, with wild-type C57BL/6 mice. Cancer, especially adenocarcinoma, is the most commonly associated disease. MSP and qPCR have been used to validate the findings of MeDIP-seq. Using this MeDIP-seq and IPA analysis, comparisons between the TRAMP and control samples reveal profound differences in gene methylation. The analysis of canonical pathways and networks has identified important biological functions and molecular pathways that may mediate the development of adenocarcinoma prostate cancer. CREB-, HDAC2-, GSTP1- and UBC-related pathways showed significantly altered methylation profiles based on the canonical pathway and network analyses. Studies on epigenetics, such as DNA methylation, suggest novel avenues and strategies for the further development of biomarkers targeted for treatment and prevention approaches for prostate cancer.

TRAMP

:   transgenic adenocarcinoma of the mouse prostate

MeDIP

:   methylated DNA immunoprecipitation

IPA

:   Ingenuity^®^ Pathway Analysis

CREB1

:   cyclic AMP (cAMP) response element-binding protein 1

HDAC2

:   histone deacetyltransferase 2

GSTP1

:   glutathione S-transferase 1

UBC

:   polyubiquitin-C

NRF2

:   nuclear factor (erythroid-derived 2)-like 2

MGMT

:   O6-alkylguanine DNA alkyltransferase

KLF6

:   Krueppel-like factor 6

DYNC1I1

:   dynein cytoplasmic 1 intermediate chain 1

SLC1A4

:   solute carrier family 1 member 4

Xrcc6bp1

:   XRCC6-binding protein 1

TTR

:   transthyretin

HNMT

:   histamine *N*-methyltransferase

CRYZ

:   crystallin zeta
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